Market Research Logo

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Overview
Therapeutics Development
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Stage of Development
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Therapy Area
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Indication
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Companies
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Universities/Institutes
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Advenchen Laboratories, LLC
Amgen Inc.
ArQule, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Asubio Pharma Co., Ltd.
AVEO Pharmaceuticals, Inc.
Bayer AG
BioArctic AB
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CardioVascular BioTherapeutics, Inc.
Celon Pharma Sp. z o.o.
Debiopharm International SA
Eddingpharm
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Hutchison MediPharma Limited
Incyte Corporation
Johnson & Johnson
Les Laboratoires Servier SAS
Metacrine Inc
Novartis AG
OncoMax
Principia Biopharma Inc.
Teva Pharmaceutical Industries Ltd.
Vichem Chemie Research Ltd.
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Drug Profiles
Aea-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aea-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARQ-087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-5878 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4547 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1163877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brivanib alaninate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEP-11981 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPL-043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141H - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Debio-1347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize Fibroblast Growth Factor Receptor 1 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-7090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FGF-1 Program - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-54828 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infigratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lucitanib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2874455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize FGFR1 for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMRCA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride + pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
regorafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7992 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-49076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-0806 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUN-11602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Dormant Projects
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Featured News & Press Releases
Nov 07, 2016: Bayer Submits Supplemental New Drug Application for Stivarga (regorafenib) for Advanced Liver Cancer
Nov 07, 2016: Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product
Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016
Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung
Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland
Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO
Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders
Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma
Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016
Sep 28, 2016: Bayer to Showcase Regorafenib at ESMO 2016 Congress
Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress
Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association
Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Advenchen Laboratories, LLC, H2 2016
Pipeline by Amgen Inc., H2 2016
Pipeline by ArQule, Inc., H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by AstraZeneca Plc, H2 2016
Pipeline by Asubio Pharma Co., Ltd., H2 2016
Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
Pipeline by Bayer AG, H2 2016
Pipeline by BioArctic AB, H2 2016
Pipeline by Boehringer Ingelheim GmbH, H2 2016
Pipeline by Bristol-Myers Squibb Company, H2 2016
Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016
Pipeline by Celon Pharma Sp. z o.o., H2 2016
Pipeline by Debiopharm International SA, H2 2016
Pipeline by Eddingpharm, H2 2016
Pipeline by Eisai Co., Ltd., H2 2016
Pipeline by Eli Lilly and Company, H2 2016
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pipeline by Hutchison MediPharma Limited, H2 2016
Pipeline by Incyte Corporation, H2 2016
Pipeline by Johnson & Johnson, H2 2016
Pipeline by Les Laboratoires Servier SAS, H2 2016
Pipeline by Metacrine Inc, H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by OncoMax, H2 2016
Pipeline by Principia Biopharma Inc., H2 2016
Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Pipeline by Vichem Chemie Research Ltd., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Dormant Projects (Contd..3), H2 2016
Dormant Projects (Contd..4), H2 2016
Discontinued Products, H2 2016
Discontinued Products (Contd..1), H2 2016
Discontinued Products (Contd..2), H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report